Technology Platform May Improve Diabetes Management
BioChaperone platform could increase the efficacy and safety of diabetes drugs.
Adocia, a biopharmaceutical company, is providing an overview of its BioChaperone technology for creating novel diabetes treatments at the American Diabetes Association (ADA) 77th Scientific Sessions.
The BioChaperone platform was developed to increase the safety and efficacy of therapeutic proteins, while also decreasing patient burden. Adocia customizes BioChaperone to each protein for a condition to address specific needs, according to a press release.
During the conference, Adocia will present the following abstracts about BioChaperone technology:
- Poster #964: Ultra-rapid BioChaperone Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 1 Diabetes (T1DM)
- Poster #994: Ultra-rapid BioChaperone Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 2 Diabetes (T2DM)
- Poster #996: Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone Lispro (BCLIS) in Healthy Japanese Subjects
- Poster #1150: Preclinical efficacy of a stable aqueous formulation of human glucagon with BioChaperone technology (BC GLU)
- Poster #1153: BioChaperone technology enables rhGlucagon aqueous formulation for use in rescue and dual hormone artificial pancreas (DHAP)
- Poster #1029: BioChaperone technology enables the development of glargine-liraglutide and glargine-dulaglutide combinations
“We are pleased to be featuring a strong and varied set of data from our programs at this year’s ADA Scientific Sessions, which gathers global leaders dedicated to improving the life of people with diabetes. This gives us the opportunity to showcase the significant progress that the company has made, particularly with our lead phase 3-ready program BioChaperone Lispro,” said Gérard Soula, chairman and CEO of Adocia. “We are also very excited to share promising data from 2 of our earlier-stage programs, BioChaperone Glucagon and our BioChaperone-enabled combinations of glargine and GLP-1 receptor agonists.”